Copy
View this email in your browser
Southampton Health Technology Assessments Centre

Welcome to the SHTAC newsletter 
Our work for the NICE HTA programme has continued a pace, we have critically appraised the following treatments:

Tofacitinib for treating active ulcerative colitis, NICE's guidance is available here

Cabozantinib for untreated advanced renal cell carcinoma colitis, NICE's guidance is available here

Ocrezlizumab for treating relapsing-remitting multiple sclerosis, NICE's guidance is available here

Atezolizumab for treating metastatic urothelial cancer after platinum-based chemotherapy, NICE's guidance is available here
SHTAC have contributed to a new report on the cost-effectiveness of tests for latent TB infection in predicting active tuberculosis

SHTAC Courses
Another busy year for the training teams, welcoming lots of people to Southampton.  All the courses we have run in 2018 have been well received. 

Booking for March 2019 courses is now open - please share this newsletter if someone in your network would be interested in one of the courses.   There is a direct booking link below.
Course bookings
Our current research projects include:
Finally, season's greetings from everyone at SHTAC
Twitter
Twitter
SHTAC website
SHTAC website
Email
Email
Our offices are closed from 24 December and reopen on Wednesday 2 January 2019
Copyright © 2018 SHTAC, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

 






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
SHTAC · Alpha House · Enterprise Road · Southampton, Hampshire SO16 7NS · United Kingdom

Email Marketing Powered by Mailchimp